Cargando…

Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy

Diabetic retinopathy (DR) is a retinal vascular disorder associated with both type 1 and type 2 diabetes mellitus (DM). It is characterized by specific loss of pericytes, which leads to an augmented blood vessel permeability, and development of new blood vessels (retinal neovascularization). Moreove...

Descripción completa

Detalles Bibliográficos
Autores principales: Zewdie, Kaleab Alemayehu, Ayza, Muluken Altaye, Amare Tesfaye, Bekalu, Yimer, Ebrahim M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323811/
https://www.ncbi.nlm.nih.gov/pubmed/32612349
http://dx.doi.org/10.2147/OPTH.S258044
_version_ 1783551840945700864
author Zewdie, Kaleab Alemayehu
Ayza, Muluken Altaye
Amare Tesfaye, Bekalu
Yimer, Ebrahim M
author_facet Zewdie, Kaleab Alemayehu
Ayza, Muluken Altaye
Amare Tesfaye, Bekalu
Yimer, Ebrahim M
author_sort Zewdie, Kaleab Alemayehu
collection PubMed
description Diabetic retinopathy (DR) is a retinal vascular disorder associated with both type 1 and type 2 diabetes mellitus (DM). It is characterized by specific loss of pericytes, which leads to an augmented blood vessel permeability, and development of new blood vessels (retinal neovascularization). Moreover, stiffening of eye membrane, inflammation, and apoptosis of endothelial cells also lead to damage of the blood–retinal barrier and blindness in most cases unless it’s detected and managed early. Hence, this review was intended to assess the potential roles of Netrin-1 and -4 as new/alternative biomarkers and therapeutic options for DR. Netrin-1 and -4 have been the most known ligands and are well known for their role in neural guidance. DR has both neural and vascular components; therefore, biomarkers used for both neural and vascular retinal tissues are potentially important. According to different experimental and clinical studies, as compared to the normal groups, there was a significant increment in both retinal Netrin-1 and -4 mRNA and protein levels in the retinopathy groups. In addition, exogenous supplementation of these proteins is also used as a therapeutic agent for DR.
format Online
Article
Text
id pubmed-7323811
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-73238112020-06-30 Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy Zewdie, Kaleab Alemayehu Ayza, Muluken Altaye Amare Tesfaye, Bekalu Yimer, Ebrahim M Clin Ophthalmol Review Diabetic retinopathy (DR) is a retinal vascular disorder associated with both type 1 and type 2 diabetes mellitus (DM). It is characterized by specific loss of pericytes, which leads to an augmented blood vessel permeability, and development of new blood vessels (retinal neovascularization). Moreover, stiffening of eye membrane, inflammation, and apoptosis of endothelial cells also lead to damage of the blood–retinal barrier and blindness in most cases unless it’s detected and managed early. Hence, this review was intended to assess the potential roles of Netrin-1 and -4 as new/alternative biomarkers and therapeutic options for DR. Netrin-1 and -4 have been the most known ligands and are well known for their role in neural guidance. DR has both neural and vascular components; therefore, biomarkers used for both neural and vascular retinal tissues are potentially important. According to different experimental and clinical studies, as compared to the normal groups, there was a significant increment in both retinal Netrin-1 and -4 mRNA and protein levels in the retinopathy groups. In addition, exogenous supplementation of these proteins is also used as a therapeutic agent for DR. Dove 2020-06-25 /pmc/articles/PMC7323811/ /pubmed/32612349 http://dx.doi.org/10.2147/OPTH.S258044 Text en © 2020 Zewdie et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Zewdie, Kaleab Alemayehu
Ayza, Muluken Altaye
Amare Tesfaye, Bekalu
Yimer, Ebrahim M
Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy
title Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy
title_full Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy
title_fullStr Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy
title_full_unstemmed Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy
title_short Targeting Netrin-1 and -4 as a Novel Diagnostic Parameter and Treatment Option for Diabetic Retinopathy
title_sort targeting netrin-1 and -4 as a novel diagnostic parameter and treatment option for diabetic retinopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323811/
https://www.ncbi.nlm.nih.gov/pubmed/32612349
http://dx.doi.org/10.2147/OPTH.S258044
work_keys_str_mv AT zewdiekaleabalemayehu targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy
AT ayzamulukenaltaye targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy
AT amaretesfayebekalu targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy
AT yimerebrahimm targetingnetrin1and4asanoveldiagnosticparameterandtreatmentoptionfordiabeticretinopathy